Fecal microbiota transfer not checked
MaaT Pharma · MaaT013
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
1 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota”In the company’s words, NCT04769895 on ClinicalTrials.gov
- Tested for
- Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD, Fecal Microbiota Transplantation
- Main trialPhase 3
- “MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as salvage therapy in steroid and JAK inhibitors-resistant GI-aGvHD patients. Given the absence of an approved 3rd line strategy or 2nd line strategy in ruxolitinib intolerant patients and the extremely poor prognosis of these patients, who are mostly left with no viable therapeutic option, a single-arm open-label design was proposed.”In the company’s words, NCT04769895 on ClinicalTrials.gov
- Other names
- MaaT013
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Unknown | Nov 2024 | MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | |
| Phase 2Completed | 25 Feb 2020 | Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer | |
| Phase 2Ended | not given | PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors | |
| Phase 2Authorised | not given | A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026